• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?

作者信息

Siebert Stefan, Millar Neal L, McInnes Iain B

机构信息

Institute of Infection Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Institute of Infection Immunity and Inflammation, University of Glasgow, Glasgow, UK

出版信息

Ann Rheum Dis. 2019 Aug;78(8):1015-1018. doi: 10.1136/annrheumdis-2018-213654. Epub 2018 Oct 8.

DOI:10.1136/annrheumdis-2018-213654
PMID:30297330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6691857/
Abstract
摘要

相似文献

1
Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?白细胞介素-23p19抑制在强直性脊柱炎中为何失败：组织、试验还是转化的问题？
Ann Rheum Dis. 2019 Aug;78(8):1015-1018. doi: 10.1136/annrheumdis-2018-213654. Epub 2018 Oct 8.
2
Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways.白细胞介素-17通过磷脂酰肌醇3激酶、核因子κB和p38丝裂原活化蛋白激酶依赖性信号通路上调类风湿关节炎滑膜成纤维细胞中白细胞介素-23p19的表达。
Rheumatology (Oxford). 2007 Jan;46(1):57-64. doi: 10.1093/rheumatology/kel159. Epub 2006 Jun 12.
3
Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis.单核细胞衍生的白细胞介素 (IL)-23 是类风湿关节炎滑膜中白细胞介素-17A 表达的重要决定因素。
J Rheumatol. 2009 Nov;36(11):2403-8. doi: 10.3899/jrheum.081304. Epub 2009 Oct 1.
4
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.中文学术文献翻译
Ann Rheum Dis. 2020 Jun;79(6):778-786. doi: 10.1136/annrheumdis-2020-217163. Epub 2020 May 7.
5
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Guselkumab 调节生物制剂初治患者与肿瘤坏死因子抑制剂应答不足的活动性银屑病关节炎患者的白细胞介素-23 信号通路。
Arthritis Rheumatol. 2024 Jun;76(6):894-904. doi: 10.1002/art.42803. Epub 2024 Mar 4.
6
Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway.白细胞介素（IL）-23 p19在类风湿关节炎患者的人成纤维样滑膜细胞中由IL-1β通过活性核因子-κB和AP-1依赖性途径诱导表达。
Rheumatology (Oxford). 2007 Aug;46(8):1266-73. doi: 10.1093/rheumatology/kem055. Epub 2007 Jun 14.
7
IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors.IL-23 在银屑病关节炎中的皮肤和关节特征：深入理解 IL-23 抑制剂临床应答的新视角。
Ann Rheum Dis. 2021 May;80(5):591-597. doi: 10.1136/annrheumdis-2020-218186. Epub 2020 Nov 26.
8
Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis.白细胞介素-36 家族失调驱动银屑病关节炎的关节炎症和治疗反应。
Rheumatology (Oxford). 2020 Apr 1;59(4):828-838. doi: 10.1093/rheumatology/kez358.
9
Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-FIL-23 CD161 CD4 T helper cells in psoriatic arthritis joints.基于像素的对比增强超声定量成像显示，银屑病关节炎关节中滑膜血管灌注与致病性白细胞介素-17A/白细胞介素-23 CD161 CD4辅助性T细胞募集之间存在线性关系。
Clin Rheumatol. 2017 Feb;36(2):391-399. doi: 10.1007/s10067-016-3500-x. Epub 2016 Dec 20.
10
Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis.白细胞介素（IL）23亚基p19在类风湿性滑膜中大量表达，但生物活性IL23水平较低：类风湿性关节炎中IL23亚基p19和p40的差异表达及Toll样受体（TLR）依赖性调控
Ann Rheum Dis. 2009 Jan;68(1):143-50. doi: 10.1136/ard.2007.082081. Epub 2008 Feb 14.

引用本文的文献

1
TNFα Inhibitors Versus Newer Therapies in Spondyloarthritis: Where do we Stand Today?肿瘤坏死因子α抑制剂与脊柱关节炎的新型疗法对比：我们如今处于什么境地？
Mediterr J Rheumatol. 2024 Dec 31;35(Suppl 3):519-527. doi: 10.31138/mjr.040224.tvn. eCollection 2024 Dec.
2
Current Concepts and Medical Management for Patients with Radiographic Axial Spondyloarthritis.影像学轴向脊柱关节炎患者的当前概念与医学管理
Hip Pelvis. 2024 Dec 1;36(4):234-249. doi: 10.5371/hp.2024.36.4.234.
3
Type 17 immunity: novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells.

本文引用的文献

1
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.利纳西珠单抗，一种白细胞介素 23 抑制剂，用于治疗强直性脊柱炎：一项随机、双盲、安慰剂对照、概念验证、剂量发现的 2 期研究结果。
Ann Rheum Dis. 2018 Sep;77(9):1295-1302. doi: 10.1136/annrheumdis-2018-213328. Epub 2018 Jun 26.
2
Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing T cells through modification of the intestinal microbiota.通过改变肠道微生物群，抑制白细胞介素-17F（IL-17F）而不是白细胞介素-17A（IL-17A）可通过诱导 T 细胞来提供对结肠炎的保护。
Nat Immunol. 2018 Jul;19(7):755-765. doi: 10.1038/s41590-018-0134-y. Epub 2018 Jun 18.
3
17 型免疫：肠道初免 T 细胞驱动的肠道稳态和自身免疫发病机制的新见解。
Cell Mol Immunol. 2024 Nov;21(11):1183-1200. doi: 10.1038/s41423-024-01218-x. Epub 2024 Oct 8.
4
Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis.主要韧带为中心的软组织受累可将脊柱关节炎与强直性脊柱炎区分开来。
Nat Rev Rheumatol. 2023 Dec;19(12):818-827. doi: 10.1038/s41584-023-01038-9. Epub 2023 Nov 2.
5
Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies.脊柱关节炎合并炎症性肠病：生物制剂和靶向治疗的最新进展。
Nat Rev Rheumatol. 2023 Aug;19(8):503-518. doi: 10.1038/s41584-023-00984-8. Epub 2023 Jun 29.
6
What do we know about co-stimulatory and co-inhibitory immune checkpoint signals in ankylosing spondylitis?我们对强直性脊柱炎中的共刺激和共抑制免疫检查点信号了解多少？
Clin Exp Immunol. 2023 Oct 13;213(3):288-300. doi: 10.1093/cei/uxad032.
7
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy.银屑病关节炎的表型异质性：迈向基于组织病理学的治疗
Nat Rev Rheumatol. 2023 Mar;19(3):153-165. doi: 10.1038/s41584-022-00874-5. Epub 2023 Jan 3.
8
Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases-RA as a role model.细胞因子及细胞因子受体作为免疫介导的炎症性疾病的靶点——以类风湿关节炎为例
Inflamm Regen. 2022 Dec 1;42(1):35. doi: 10.1186/s41232-022-00221-x.
9
Precision medicine: the precision gap in rheumatic disease.精准医学：风湿性疾病中的精准差距。
Nat Rev Rheumatol. 2022 Dec;18(12):725-733. doi: 10.1038/s41584-022-00845-w. Epub 2022 Oct 10.
10
The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis.IL-23 的作用及 IL-23 抑制剂在银屑病关节炎中的应用。
Musculoskeletal Care. 2022 Nov;20 Suppl 1(Suppl 1):S12-S21. doi: 10.1002/msc.1694. Epub 2022 Sep 7.
T17 cell plasticity: The role of dendritic cells and molecular mechanisms.
T17 细胞可塑性：树突状细胞的作用和分子机制。
J Autoimmun. 2018 Feb;87:50-60. doi: 10.1016/j.jaut.2017.12.003. Epub 2018 Jan 19.
4
Anti‑IL‑39 (IL‑23p19/Ebi3) polyclonal antibodies ameliorate autoimmune symptoms in lupus‑like mice.抗白细胞介素 39（白细胞介素 23p19/Ebi3）多克隆抗体可改善狼疮样小鼠的自身免疫症状。
Mol Med Rep. 2018 Jan;17(1):1660-1666. doi: 10.3892/mmr.2017.8048. Epub 2017 Nov 14.
5
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.替西单抗与安慰剂或依那西普治疗慢性斑块型银屑病（reSURFACE 1 和 reSURFACE 2）：两项随机对照、3 期临床试验的结果。
Lancet. 2017 Jul 15;390(10091):276-288. doi: 10.1016/S0140-6736(17)31279-5. Epub 2017 Jun 6.
6
Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis.简报：人类附着点中的第 3 组固有淋巴细胞。
Arthritis Rheumatol. 2017 Sep;69(9):1816-1822. doi: 10.1002/art.40150. Epub 2017 Aug 8.
7
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.利纳西珠单抗与乌司奴单抗治疗中重度斑块状银屑病的疗效比较。
N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017.
8
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.在中重度克罗恩病患者中使用选择性白细胞介素-23 抑制剂 risankizumab 进行诱导治疗：一项随机、双盲、安慰剂对照的 2 期研究。
Lancet. 2017 Apr 29;389(10080):1699-1709. doi: 10.1016/S0140-6736(17)30570-6. Epub 2017 Apr 12.
9
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗相比，用于中重度银屑病患者的连续治疗：来自 III 期、双盲、安慰剂和活性对照 VOYAGE 1 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2.
10
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.乌司奴单抗诱导和维持治疗克罗恩病。
N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773.